StockWatch
·
Surgical & Medical Instruments & Apparatus
Corporate ActionJul 24, 2026, 04:57 PM

Allurion Terminates Debt-for-Equity Deal; Exchanges Stock for Warrants

AI Summary

Allurion Technologies terminated a Securities Purchase and Exchange Agreement with RTW affiliates, which would have converted outstanding debt, including Revenue Interest Financing Agreements and 6% Convertible Secured Notes, into Series B Preferred Stock. As a result, this debt remains outstanding under its original terms. Concurrently, the company entered a new Exchange Agreement with the same RTW affiliates, exchanging 392,766 shares of common stock for an equal number of pre-funded warrants. These warrants have a nominal exercise price of $0.0001 per share and will automatically terminate if RTW forecloses on the RIFAs/Notes or if Allurion files for bankruptcy.

Key Highlights

  • Allurion terminated a Securities Purchase and Exchange Agreement with RTW affiliates.
  • The terminated agreement would have exchanged outstanding debt for Series B Preferred Stock.
  • Debt, including RIFAs and 6% Convertible Secured Notes, remains outstanding.
  • Company entered new Exchange Agreement with RTW affiliates.
  • 392,766 common shares were exchanged for pre-funded warrants.
  • Warrants allow purchase of 392,766 shares at $0.0001 exercise price.
  • Warrants terminate upon foreclosure by RTW on RIFAs/Notes or company bankruptcy.
  • RTW affiliates owned approximately 38% of common stock before the exchange.